J Jankovic

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Evidence-based review of patient-reported outcomes with botulinum toxin type A
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 27:234-44. 2004
  2. ncbi request reprint Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Dept of Neurology, Baylor College of Medicine, Houston, TX 77030, USA Electronic address
    Parkinsonism Relat Disord 20:640-3. 2014
  3. pmc Current approaches to the treatment of Parkinson's disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine
    Neuropsychiatr Dis Treat 4:743-57. 2008
  4. doi request reprint Diagnosis and treatment of complications related to deep brain stimulation hardware
    José Fidel Baizabal Carvallo
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 26:1398-406. 2011
  5. ncbi request reprint Tourette's syndrome and the law
    Joseph Jankovic
    Parkinson s Disease Center and Movement Diorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neuropsychiatry Clin Neurosci 18:86-95. 2006
  6. ncbi request reprint Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Neurol 64:676-82. 2007
  7. ncbi request reprint Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 60:1186-8. 2003
  8. ncbi request reprint A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Smith 1801, Houston, TX 77030, USA
    Parkinsonism Relat Disord 8:271-6. 2002
  9. ncbi request reprint Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mov Disord 20:S11-6. 2005
  10. ncbi request reprint Levodopa strengths and weaknesses
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 58:S19-32. 2002

Detail Information

Publications142 found, 100 shown here

  1. ncbi request reprint Evidence-based review of patient-reported outcomes with botulinum toxin type A
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 27:234-44. 2004
    ..These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent...
  2. ncbi request reprint Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Dept of Neurology, Baylor College of Medicine, Houston, TX 77030, USA Electronic address
    Parkinsonism Relat Disord 20:640-3. 2014
    ..The ADAGIO study included a large cohort of patients with early PD (baseline total-UPDRS = 20) who were initially randomized to rasagiline and placebo, thereby allowing analyses of symptomatic efficacy...
  3. pmc Current approaches to the treatment of Parkinson's disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine
    Neuropsychiatr Dis Treat 4:743-57. 2008
    ....
  4. doi request reprint Diagnosis and treatment of complications related to deep brain stimulation hardware
    José Fidel Baizabal Carvallo
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 26:1398-406. 2011
    ..Our aim is to provide a guide for clinicians and medical staff involved in the treatment of patients with deep brain stimulation for rapid recognition and efficient management of these complications...
  5. ncbi request reprint Tourette's syndrome and the law
    Joseph Jankovic
    Parkinson s Disease Center and Movement Diorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neuropsychiatry Clin Neurosci 18:86-95. 2006
    ..The medical-legal community must learn to recognize the vulnerability of this patient population to potential mistreatment by the courts of justice...
  6. ncbi request reprint Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Neurol 64:676-82. 2007
    ..To assess the response to the rotigotine transdermal system (Neupro; Schwarz Pharma Ltd, Monheim, Germany), a nonergolinic dopamine agonist, in patients with early Parkinson disease...
  7. ncbi request reprint Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 60:1186-8. 2003
    ..004). The current preparation decreased the risk of antibody formation by a factor of six. The authors conclude that the low risk of antibody formation after current BTX type A treatment is related to lower protein load...
  8. ncbi request reprint A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Smith 1801, Houston, TX 77030, USA
    Parkinsonism Relat Disord 8:271-6. 2002
    ....
  9. ncbi request reprint Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mov Disord 20:S11-6. 2005
    ..Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention...
  10. ncbi request reprint Levodopa strengths and weaknesses
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 58:S19-32. 2002
    ..However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management...
  11. ncbi request reprint Parkinson's disease and movement disorders: moving forward
    Joseph Jankovic
    Parkinson s Disease and Movement disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Lancet Neurol 7:9-11. 2008
  12. doi request reprint Parkinson's disease: clinical features and diagnosis
    J Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030 3498, USA
    J Neurol Neurosurg Psychiatry 79:368-76. 2008
    ..This review describes the clinical characteristics of PD with emphasis on those features that differentiate the disease from other parkinsonian disorders...
  13. ncbi request reprint Botulinum toxin for the treatment of cervical dystonia
    R Tintner
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Expert Opin Pharmacother 2:1985-94. 2001
    ....
  14. doi request reprint Movement disorders in musicians
    Joseph Jankovic
    Parkinson s Disease Center, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 23:1957-65. 2008
    ..To increase professional and public awareness and to facilitate the recognition of music-related neurological problems, we suggest that "medical problems of musicians" be included in curriculum of music schools and medical schools...
  15. ncbi request reprint Prevalence of cervical dystonia and spasmodic torticollis in the United States general population
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Parkinsonism Relat Disord 13:411-6. 2007
    ..To examine the prevalence of cervical dystonia (CD) in the US population...
  16. ncbi request reprint Treatment of dystonia
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Lancet Neurol 5:864-72. 2006
    ....
  17. ncbi request reprint Botulinum toxin therapy for cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurotox Res 9:145-8. 2006
    ..This review provides and update on the treatment of CD with BoNT type A (BOTOX, Dysport, Xeomin and BoNT type B (Myobloc, NeuroBloc...
  18. ncbi request reprint Essential tremor among children
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin St, Suite 1801, Houston, TX 77030, USA
    Pediatrics 114:1203-5. 2004
    ..To characterize the clinical and therapeutic aspects of essential tremor (ET) among children...
  19. ncbi request reprint Psychogenic tremor: long-term outcome
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    CNS Spectr 11:501-8. 2006
    ..Psychogenic movement disorders are increasingly encountered in specialized clinics, and represent approximately 15% of all patients evaluated in the Baylor College of Medicine Movement Disorders Clinic...
  20. ncbi request reprint An update on the treatment of Parkinson's disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, The Smith Tower, Suite 1801, 6550 Fannin, Houston, TX 77030, USA
    Mt Sinai J Med 73:682-9. 2006
    ....
  21. ncbi request reprint Exploring the relationship between essential tremor and Parkinson's disease
    Joohi Shahed
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, TX, USA
    Parkinsonism Relat Disord 13:67-76. 2007
    ..We examine here the evidence for and against an association between ET and PD, and critically review data supporting the notion that a subset of ET patients is predisposed to developing PD...
  22. pmc Botulinum toxin in clinical practice
    J Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurol Neurosurg Psychiatry 75:951-7. 2004
    ..Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications...
  23. ncbi request reprint Treatment of cervical dystonia with botulinum toxin
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 19:S109-15. 2004
    ..Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated...
  24. pmc Genetic mouse models of essential tremor: are they essential?
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Invest 115:584-6. 2005
    ....
  25. ncbi request reprint Searching for a relationship between manganese and welding and Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 64:2021-8. 2005
    ..The controversy has stimulated this review, the primary aim of which is to critically and objectively examine the evidence or lack of evidence for a relationship among welding, manganese, parkinsonism, and PD...
  26. doi request reprint Peripherally induced movement disorders
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Neurol Clin 27:821-32, vii. 2009
    ..The pathophysiology of these disorders is reviewed...
  27. doi request reprint Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders
    Joseph Ferrara
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    J Neuropsychiatry Clin Neurosci 23:141-8. 2011
    ..Although the tingling sensation produced by TENS makes it poorly suited for a controlled clinical trial, the device has a favorable side-effect profile and is an acceptable palliative treatment for a subset of PMD patients...
  28. ncbi request reprint The evolution of diagnosis in early Parkinson disease. Parkinson Study Group
    J Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Neurol 57:369-72. 2000
    ..Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD...
  29. ncbi request reprint Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006
    ..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
  30. pmc Re-emergent tremor of Parkinson's disease
    J Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurol Neurosurg Psychiatry 67:646-50. 1999
    ..It is postulated that one type of postural tremor in Parkinson's disease represents a rest tremor that re-emerges after a variable delay while maintaining posture, hence "re-emergent tremor"...
  31. doi request reprint Diagnosis and treatment of psychogenic parkinsonism
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, The Smith Tower, Suite 1801 6550 Fannin Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 82:1300-3. 2011
    ....
  32. ncbi request reprint Levodopa-induced dyskinesias treated by pallidotomy
    J Jankovic
    Baylor College of Medicine, Dir of Parkinson s Disease Ctr and Movement Disorders Ctr, 6550 Fannin 1801, Houston, TX 77030, USA
    J Neurol Sci 167:62-7. 1999
    ..We conclude that pallidotomy is an effective and safe procedure in the treatment of medically intractable LID...
  33. doi request reprint Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Houston, TX, USA
    Expert Rev Neurother 11:1509-23. 2011
    ....
  34. ncbi request reprint Botulinum toxin: historical perspective and potential new indications
    J Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Muscle Nerve Suppl 6:S129-45. 1997
    ..Patient selection and the proper choice of dose and administration site are the most important determinants of a favorable response to BTX treatment...
  35. ncbi request reprint Essential tremor: a heterogenous disorder
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 17:638-44. 2002
  36. doi request reprint Tourette's syndrome in adults
    Joseph Jankovic
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 25:2171-5. 2010
    ..In addition, adults with TS are more likely to exhibit substance abuse and mood disorders compared with children with TS...
  37. ncbi request reprint Dystonia and parkinsonism
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Parkinsonism Relat Disord 8:109-21. 2001
    ....
  38. ncbi request reprint Functional decline in Parkinson disease
    J Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Arch Neurol 58:1611-5. 2001
    ..To determine the overall rate of functional decline and to assess the progression of different signs of Parkinson disease (PD)...
  39. doi request reprint Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease
    Joseph Ferrara
    Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 81:315-9. 2010
    ..In this study, we evaluate the effect of STN DBS on quality of life using the QLS(M), a modular questionnaire in which satisfaction scores for each item are weighted in light of patient-rated importance...
  40. doi request reprint A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome
    J Jankovic
    Baylor College of Medicine, Department of Neurology, Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 81:70-3. 2010
    ..To investigate the effects of topiramate on Tourette syndrome (TS)...
  41. doi request reprint Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm
    J Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Eur J Neurol 16:14-8. 2009
    ..1% Xeomin and 4.5% Botox). Conclusion: Clinical evidence to date suggests that Xeomin is an effective treatment for blepharospasm that does not differ from Botox in terms of its potency, duration of effect or adverse reaction profile...
  42. doi request reprint Treatment of hyperkinetic movement disorders
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Lancet Neurol 8:844-56. 2009
    ..Finally, success with surgical approaches, particularly deep brain stimulation in patients with Parkinson's disease who have levodopa-induced dyskinesias, has been extended to the treatment of many hyperkinetic movement disorders...
  43. doi request reprint Preclinical biomarkers of Parkinson disease
    Yuncheng Wu
    Department of Neurology, Shanghai First People s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Arch Neurol 68:22-30. 2011
    ....
  44. ncbi request reprint Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease
    H Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 65:651-2. 2005
  45. ncbi request reprint Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury
    W Le
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurochem 73:2218-21. 1999
    ..This study suggests that Nurr1 may play an important role in maintaining mature mesencephalic dopaminergic neuron function and that a defect in Nurr1 may increase susceptibility to SN injury...
  46. ncbi request reprint Variability and validity of polymorphism association studies in Parkinson's disease
    E K Tan
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Neurology 55:533-8. 2000
    ..In recent years, interest in gene-environment interactions has spurred a great number of association studies on polymorphism of different genes...
  47. ncbi request reprint Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease
    M K York
    Baylor College of Medicine, Department of Neurology, 6501 Fannin, NB302, Houston, Texas 77030, USA
    J Neurol Neurosurg Psychiatry 79:789-95. 2008
    ..We investigated the cognitive and psychiatric outcome 6 months after bilateral subthalamic nucleus deep brain stimulation (DBS) for the treatment of Parkinson's disease (PD) using a disease control group...
  48. ncbi request reprint Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection
    W D Le
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Neural Transm 107:1165-73. 2000
    ..5 cells. These results indicate that pramipexole's neuroprotective effects are likely associated with its antioxidant property independent of D2/D3 receptor activation...
  49. ncbi request reprint Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial
    R Tintner
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Neurology 65:765-7. 2005
    ..Patients treated with BTX-B had less saliva production (p < 0.01) and greater severity of constipation (p = 0.037) than those treated with BTX-A, but did not differ in other tests of autonomic functions...
  50. doi request reprint Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D M Simpson
    Department of Neurology, Mount Sinai Medical Center, New York, NY, USA
    Neurology 70:1699-706. 2008
    ..To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders...
  51. pmc The impact of depressive symptoms in early Parkinson disease
    B Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Neurology 69:342-7. 2007
    ..No previous study has systematically examined the impact of depressive symptoms in early, untreated PD...
  52. ncbi request reprint Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls
    W Ondo
    Department of Neurlogy, Baylor College of Medicine, Houston, Texas, USA
    Arch Neurol 57:1464-9. 2000
    ..Progressive supranuclear palsy (PSP) is a neurodegenerative disorder that is frequently mistaken for Parkinson's disease (PD) in its early stages...
  53. ncbi request reprint Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
    ..6%), and akathisia (7.6%). Comparison of log-likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long-term treatment of hyperkinetic movement disorders...
  54. doi request reprint Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease
    D F Marshall
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Eur J Neurol 19:1525-31. 2012
    ....
  55. doi request reprint Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease
    A M Strutt
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Eur J Neurol 19:121-7. 2012
    ..Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to have beneficial effects on the motor features of Parkinson's disease (PD), but its impact on non-motor symptoms, most notably mood, has not been fully explored...
  56. ncbi request reprint Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome
    H Deng
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Acta Neurol Scand 114:400-2. 2006
    ..To determine whether variants in the Slit and Trk-like 1 gene (SLITRK1) are present in American Caucasian population of patients with Tourette syndrome (TS)...
  57. pmc Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
    David K Simon
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 11:53. 2010
    ..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD...
  58. ncbi request reprint Topiramate in essential tremor: a double-blind, placebo-controlled trial
    W G Ondo
    Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 66:672-7. 2006
    ..Additional therapies are required for patients with an inadequate response or intolerable side effects. In small trials, topiramate appeared to be beneficial in essential tremor...
  59. ncbi request reprint Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    W D Le
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs Aging 18:389-96. 2001
    ....
  60. ncbi request reprint The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
    J Jankovic
    Department of Neurology, Parkinson Disease Research Lab, Baylor College of Medicine, Houston, TX 77030, USA
    Prog Neurobiol 77:128-38. 2005
    ..All these studies suggest that Nurr1 is not only essential in the development of mensencephalic dopaminergic neurons and maintenance of their functions, but it may also play a role in the pathogenesis of PD...
  61. ncbi request reprint Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis
    M K York
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Acta Neurochir (Wien) 149:857-66; discussion 866. 2007
    ..We investigated retrospectively the short and long-term motor and cognitive functioning of staged bilateral pallidotomy using motor testing and a comprehensive neuropsychological battery before and after each procedure...
  62. ncbi request reprint Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
    R L Watts
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233 0017, USA
    Neurology 68:272-6. 2007
    ....
  63. pmc The effect of deep brain stimulation on quality of life in movement disorders
    A Diamond
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Street, Suite 1801, Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 76:1188-93. 2005
    ..We systematically and critically reviewed the literature on the effects of DBS on HRQoL in PD, ET, dystonia, and cerebellar outflow tremor related to multiple sclerosis...
  64. ncbi request reprint Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease
    P Y Xu
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 58:881-4. 2002
    ..To determine whether the Nurr1 gene, which is critical for the development and maintenance of nigral dopaminergic neurons, is a risk factor associated with PD...
  65. ncbi request reprint Thalamic deep brain stimulation: effects on the nontarget limbs
    W Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 16:1137-42. 2001
    ..We conclude that VIM DBS may mildly improve ipsilateral ET, and that concerns about meaningful ipsilateral tremor augmentation after device deactivation are not warranted...
  66. ncbi request reprint Daytime sleepiness and other sleep disorders in Parkinson's disease
    W G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Neurology 57:1392-6. 2001
    ..PD is associated with a variety of sleep problems. The dopamine agonists (DA) pramipexole and ropinirole were recently implicated in causing "sleep attacks" and motor vehicle accidents...
  67. ncbi request reprint Dystonia in corticobasal degeneration
    Z Vanek
    Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 16:252-7. 2001
    ..Axial or leg dystonia, without significant involvement of an arm, is rare. There is no effective treatment for this relentless disorder, except for temporary relief of dystonia and pain, with local botulinum toxin injections...
  68. ncbi request reprint Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application
    J K Krauss
    Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
    Neurosurgery 48:535-41; discussion 541-3. 2001
    ..To rationalize the technique and reduce the costs associated with chronic deep brain stimulation of the thalamus for treatment of refractory tremor...
  69. ncbi request reprint Thalamic deep brain stimulation: comparison between unilateral and bilateral placement
    W Ondo
    Department of Neurology, Baylor College of Medicine, 6550 Fannin Dr, Suite 1801, Houston, TX 77030, USA
    Arch Neurol 58:218-22. 2001
    ..There are, however, relatively little data concerning bilateral thalamic DBS and no thorough comparisons between the 2 methods...
  70. ncbi request reprint Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
    Clin Neuropharmacol 30:256-65. 2007
    ....
  71. ncbi request reprint Tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    Expert Rev Neurother 6:7-17. 2006
    ....
  72. ncbi request reprint Comparison of thalamotomy and pallidotomy for the treatment of dystonia
    D Yoshor
    Department of Neurosurgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Neurosurgery 48:818-24; discussion 824-6. 2001
    ..In this study, we compare our results using thalamotomy and pallidotomy to treat patients with different forms of dystonia, and we discuss our results in the context of other published series...
  73. ncbi request reprint Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    Expert Opin Pharmacother 8:1329-35. 2007
    ..Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties...
  74. doi request reprint Genetic study of an American family with DYT3 dystonia (lubag)
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 448:180-3. 2008
    ..In contrast, TAF1 and CXCR3 gene expression in peripheral blood lymphocytes is not a suitable surrogate disease marker for DYT3...
  75. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  76. doi request reprint A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    ..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
  77. doi request reprint Atomoxetine for freezing of gait in Parkinson disease
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, United States
    J Neurol Sci 284:177-8. 2009
    ..Further studies in a larger population of patients with FoG are needed to determine whether atomoxetine is a useful drug in the treatment of this, often disabling, feature of PD...
  78. ncbi request reprint Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
    Behzod Z Dolimbek
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mol Immunol 44:1029-41. 2007
    ..The molecular and clinical implications of these findings are discussed...
  79. ncbi request reprint Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Neurol 63:273-7. 2006
    ..Mutations in the parkin gene (PRKN) cause autosomal recessive early-onset Parkinson disease (EOPD)...
  80. ncbi request reprint Long-term botulinum toxin efficacy, safety, and immunogenicity
    Nicte I Mejia
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 20:592-7. 2005
    ..Except for 1 patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment...
  81. pmc Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial
    W G Ondo
    Baylor College of Medicine, Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 76:1636-9. 2005
    ..The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions...
  82. ncbi request reprint Hearing impairment in essential tremor
    W G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, USA
    Neurology 61:1093-7. 2003
    ..To assess hearing in patients with essential tremor (ET) vs patients with Parkinson disease (PD) and normal controls...
  83. ncbi request reprint GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities
    J Shahed
    Parkinson s Disease Center, and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 68:159-60. 2007
  84. ncbi request reprint Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol
    W G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Psychiatry 156:1279-81. 1999
    ..Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tetrabenazine for tardive dyskinesia...
  85. doi request reprint Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education
    O R Adam
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurology 73:e50-2. 2009
    ..Such data might provide insights which augment patient care, and may be instructive regarding medical education, since patient-related telephone calls are often addressed by physicians-in-training...
  86. ncbi request reprint Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease
    James K Sheffield
    Department of Neurology, Baylor College of Medicine, Parkinson s Disease Center and Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Expert Rev Neurother 7:637-47. 2007
    ....
  87. ncbi request reprint Mutations in NR4A2 associated with familial Parkinson disease
    Wei Dong LE
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
    Nat Genet 33:85-9. 2003
    ..Additionally, mutations in NR4A2 affect transcription of the gene encoding tyrosine hydroxylase. These data suggest that mutations in NR4A2 can cause dopaminergic dysfunction, associated with Parkinson disease...
  88. ncbi request reprint Tetrabenazine treatment for Huntington's disease-associated chorea
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 25:300-2. 2002
    ..TBZ was well tolerated and resulted in a significant improvement in modified AIMS scores in HD patients. These results support the use of TBZ for chorea in patients with HD...
  89. ncbi request reprint Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    CNS Drugs 21:677-92. 2007
    ....
  90. ncbi request reprint Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families
    Hao Deng
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Neurosci Lett 430:18-22. 2008
    ..The results may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling...
  91. ncbi request reprint Exploring the relationship between Parkinson disease and restless legs syndrome
    William G Ondo
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030
    Arch Neurol 59:421-4. 2002
    ..Restless legs syndrome (RLS) and Parkinson disease (PD) are common neurological conditions that respond to dopaminergic therapy. To our knowledge, the relationship between the two has not been thoroughly explored...
  92. doi request reprint Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mol Immunol 45:3878-88. 2008
    ..These regions afford candidates for epitope-specific manipulation of anti-toxin immune responses...
  93. doi request reprint Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial
    Joseph M Ferrara
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    J Neurol Sci 285:195-7. 2009
    ..Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness...
  94. ncbi request reprint The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor
    Alan Diamond
    Department of Neurology, Baylor College of Medicine, United States
    J Neurol Sci 260:199-203. 2007
    ..9% (p=0.008) and upper extremity 92.5% (p=0.008) TRS subscore. Functional improvement was noted with pouring liquids. Our findings provide support that STN DBS is an effective treatment of tremor associated with PD...
  95. ncbi request reprint Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease
    Chuantao Jiang
    Parkinson Disease Research Lab, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Clin Neuropharmacol 27:63-73. 2004
    ....
  96. ncbi request reprint A peptide-based immunoassay for antibodies against botulinum neurotoxin A
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Mol Recognit 20:15-21. 2007
    ....
  97. ncbi request reprint Subthalamic deep brain stimulation in patients with a previous pallidotomy
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 21:1252-4. 2006
    ..This may be partially due to a selection bias, but it may also indicate that prior pallidotomy is a negative predictor of outcome of STN DBS and should be considered in patient selection...
  98. ncbi request reprint Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, New York, NY 10029, USA
    Mov Disord 20:S3-10. 2005
    ..If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa...
  99. ncbi request reprint An open-label pilot study of levetiracetam for essential tremor
    William G Ondo
    Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA
    Clin Neuropharmacol 27:274-7. 2004
    ..Adverse events included dizziness (n=2), sedation (n=1), and nervousness (n=1). Levetiracetam was well tolerated but failed to improve tremor consistently in this small trial...
  100. ncbi request reprint Short-term effects of tetrabenazine on chorea associated with Huntington's disease
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:10-3. 2007
    ..2 hours to a maximum of 8.1 hours (mean = 5.4 +/- 1.3). No patient experienced an adverse event related to TBZ or its withdrawal. During short-term follow-up after a single dose, TBZ improves chorea for approximately 5 hours...